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Dry eye disease (DED) is a complex, multifactorial pathology characterized by corneal epithelium lesions
and inﬂammation. The aim of the present study was to evaluate the efﬁcacy of a cationic emulsion of
cyclosporine A (CsA) in a mouse model that mimics severe dry eye. Eight to 12-week-old female C57BL/
6N mice with tail patches of scopolamine were housed in controlled environment chambers to induce
dry eye. At day three, following dry eye conﬁrmation by corneal ﬂuorescein staining (CFS, score 0e15)
and phenol red thread (PRT) lacrimation test, the mice (n ¼ 10/gp) were either treated 3 times a day in
both eyes with drug-free cationic emulsion, a 0.1% CsA cationic emulsion, or 1% methylprednisolone
(positive control), or non-treated. Aqueous tear production and CFS scores were evaluated at baseline
and throughout the treatment period. The lacrimation test conﬁrmed the scopolamine-induced decrease
in aqueous production by the lacrimal gland. A reduction of 59% in induced-CFS was observed following
topical treatment with 0.1% CsA. The beneﬁcial effect of the cationic emulsion vehicle itself on keratitis
was also clearly evidenced by its better performance over 1% methylprednisolone, -36%, vs. -28% on the
CFS scores, respectively. This study indicates that the cationic emulsion of CsA (0.1%) was a very effective
formulation for the management of corneal epithelium lesions in a severe DED mouse model. In addition,
it performed better than a potent glucocorticosteroid (1% methylprednisolone). This cationic emulsion of
CsA (0.1%), combining CsA and a tear ﬁlm oriented therapy (TFOT), i.e. with vehicle properties that
mechanically stabilize the tear ﬁlm, represents a promising new treatment strategy for the management
of the signs of dry eye.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Dry eye disease (DED) is a complex multifactorial pathology
characterized by corneal epithelium lesions, inﬂammation of ocular
surface and symptoms of discomfort (DEWS, 2007). Taken indi-
vidually, the severity of the lesions (signs) or symptoms are often
correlated with the severity of the disease (Amparo et al., 2015;
Baudouin et al., 2014), while taken together the severity of signs
and symptoms do not necessarily correlate (Bartlett et al., 2015;
Schmidl et al., 2015). DED is therefore difﬁcult to treat as both
signs and symptoms, which do not correlate well and are modu-
lated upon treatment within different timeframes, need to be(J.-S. Garrigue).
Ltd. This is an open access article uimproved concomitantly. Artiﬁcial tears, with their good safety
proﬁle, represent the ﬁrst line therapy for the management of DED
patients, and were demonstrated to be able to alleviate mild to
moderate symptoms of DED (Alves et al., 2013; Moshirfar et al.,
2014; Williamson et al., 2014). The mechanical restoration to-
wards a normal precorneal tear ﬁlm (TF) with tear substitutes using
various technical strategies like water retention gels, or tear ﬁlm
lipid layer (TFLL) restoration (for example with cationic emulsion)
was sufﬁcient to temporarily improve the ocular discomfort
symptoms of DED patients (Amrane et al., 2014; Amrane and
Lambert, 2008; McCann et al., 2012). While both strategies are
well accepted by DED patients, TFLL restoration with cationic
emulsion is a new approach and allows for the restoration of a
structurally more natural precorneal TF with its three layers (TFLL,
aqueous layer and glycocalyx). Interestingly, it seems that TFLL
restoration approach possesses better outcomes for DED patients innder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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patients (Amrane et al., 2014; Ismail et al., 2014). Tear ﬁlm insta-
bility (http://www.dryeye.ne.jp/en/tfot/index.html) (Yokoi et al.,
1996, 2015) and inﬂammation (Wei and Asbell, 2014) of the
ocular surface have both been recognized as the core mechanism of
DED. Inﬂammationwas indeed demonstrated to have a central role
in the DED vicious cycle (Baudouin, 2007), and to be a major
contributor to the severity of both signs and symptoms (Bron et al.,
2014; Calonge et al., 2010). As such, anti-inﬂammatory drugs, such
as methylprednisolone or the immunosuppressant drug cyclo-
sporine A (CsA), with anti-inﬂammatory properties, have been
proven useful for the management of DED patients (Byun et al.,
2012; Marsh and Pﬂugfelder, 1999; Pﬂugfelder, 2004; Stonecipher
et al., 2005). It has been demonstrated experimentally, in in vitro
and animal models, that both drugs are effective at reducing
inﬂammation in corneal epithelial cells. Recently, cationic
emulsion-based artiﬁcial tears were developed as a new tear sub-
stitute, for the treatment of DED symptoms (Amrane et al., 2014;
Ismail et al., 2014), and as a vehicle for CsA (Daull et al., 2013), to
improve the ocular drug delivery through its peculiar electrostatic
interactions with the negatively charged corneal epithelium (Daull
et al., 2014; Lallemand et al., 2012). The aim of the present study
using a validated murine model of dry eye (Barabino et al., 2005)
was to assess the efﬁcacy of the cationic emulsion of CsA (Ikervis,
1 mg/ml CsA), and its vehicle in the management of DED-induced
ocular surface damages.
2. Methods
2.1. Animals
Forty pigmented C57BL/6N mice aged 8e11 weeks (Centre
d’elevage JANVIER, Le Genest Saint Isle, France) were used in this
study. Iris Pharma Internal Ethics Committee approved the proto-
col. All animals were treated according to the Directive 2010/63/UE
European Convention for the Protection of Vertebrate Animals used
for Experimental and Other Scientiﬁc Purposes and to the Associ-
ation for Research in Vision and Ophthalmology (ARVO) statement
for the Use of Animals in Ophthalmic and Vision Research.
2.2. Experimental procedure
Mice were placed in a controlled environmental chamber (CEC)
for 10 days (temperature: 20e22 C; relative humidity:<25%;
airﬂow: 15 L/min), and treated with transdermal scopolamine
patch administration (0.5 mg/72h, Scopoderm® TTS, Novartis,
Reuil-Malmaison, France) on Day 1, 3, 5, 7 and 9 adapted from
previously described model (Barabino et al., 2005).
The mice were then randomly assigned to 4 groups, including a
control group according to the corneal ﬂuorescein staining (CFS)
values at baseline (before any treatment and induction). All treat-
ments were preservative-free and prepared under a laminar ﬂow
hood in 250 mL aliquots. The aliquots were stored at room tem-
perature and one fresh aliquot was used each day for each treat-
ment group. Ten mice per group received one of the tested
solutions: 1% methylprednisolone in 0.9% NaCl solution (Methyl-
prednisolone®, Sigma-Aldrich, Saint-Quentin Fallavier, France),
0.1% cyclosporine A (Ikervis®, Santen, Evry, France) and Ikervis®
vehicle (Santen, Evry, France). Three microliters of the test items
were instilled three times a day in both eyes from Day 4e10. The
control group did not receive any eye drop treatment. The treat-
ments were encoded, and the group allocation was blinded to the
technician administering the treatment, and to the researcher
assessing the outcome of the experiment. Group identiﬁcation was
uncovered at the end of the analysis.Tear volume was measured with phenol red thread (PRT) test
(Zone-Quick, Lacrimedics, Eastsound, WA, USA), as described pre-
viously (Barabino et al., 2014). Corneal ﬂuorescein staining (eval-
uated using the National Eye Institute scheme) was performed
before dry eye induction (Day 0), and during the experiment at days
3, 6 and 10 according to a previously published protocol (Barabino
et al., 2014). Brieﬂy, 0.5 mL of a 0.5% ﬂuorescein sodium solution
(Fluoresceine Faure, 0.4-mL unit-dose vials, Novartis Pharma SAS,
France) was instilled into the inferior conjunctival sac using a
micropipette. The cornea was examined through a biomicroscope
by light passing through a cobalt blue ﬁlter. The stained area was
assessed and graded using the grading system from the NEI/In-
dustry Workshop guideline (Lemp, 1995). The system provided a
stepwise categorization of the cornea, by dividing it into ﬁve sec-
tors; with each one of them scored on a 0e3 scale, for a total
maximal score of 15.
2.3. Statistical analysis
The statistical analysis was performed using the software
GraphPad Prism 6.0b. Data were ﬁrst evaluated for normality with
D'agostino-Pearson normality test. Appropriate parametric or non-
parametric statistical tests were used to make comparisons be-
tween groups or time-points. Within group, changes from baseline
were analyzed with Friedman's test for repeated measures. The
drug effect was assessed on the corneal ﬂuorescein staining which
was considered as the primary outcome. The comparison of treated
groups was performed with dry eye-induced and non-treated
group. To take into account the baseline PRT, the CFS was
analyzed between groups using Cochran-Mantel-Haenszel method
with baseline PRT as stratiﬁcation variable. Statistical signiﬁcance
was set at a p value of 0.05. Results are presented as mean ± SD.
3. Results
3.1. Improvement of DED clinical signs: lacrimation
DED was induced in C57BL/6N mice receiving a new scopol-
amine patch every other day and placed in a controlled environ-
ment chamber (CEC, ie. in a dry and constantly ventilated
environment (Barabino et al., 2005)). For all groups, the tear vol-
ume decreased at day 3 when compared to the baseline values
(Fig. 1A). The mean tear volume values (±SD) at day 3 post DED
induction was 2.9 ± 1.5, 2.0 ± 0.6, 2.2 ± 0.6 and 2.0 ± 0.6 for un-
treated, 1% methylprednisolone, Ikervis vehicle and Ikervis groups,
respectively. These PRT values were in the range of PRT values for
mouse DED with the environmental chamber þ scopolamine
model (historical data), thus conﬁrming DED induction. The PRT
measurement variability is relatively important which may limit its
usefulness as an efﬁcacy endpoint. Upon treatment, tear volume
tend to gradually increase to baseline values, with day 10 mean
lacrimation values being not statistically different from baseline in
the animals of the three treatment groups (Ikervis, Ikervis vehicle
and 1% methylprednisolone), as a consequence of the low PRT
baseline value for these groups. Compared to 1% methylpredniso-
lone or cationic emulsion (Ikervis vehicle), the CsA-containing
cationic emulsion (Ikervis) seemed to show a better improvement
in tear volume (Fig. 1b). However those improvements were not
statistically signiﬁcant among the groups.
3.2. Improvement of DED clinical signs: corneal ﬂuorescein staining
(CFS)
CFS scores increased dramatically as soon as two days after dry
eye induction. The change was statistically signiﬁcant for all groups
aUntreated 1 % MePred Ikervis Veh Ikervis
0
2
4
6
8
10
PR
T 
(m
m
)
Baseline
Day 3 - before treatment
Day 6
Day10
Lacrimation over time
**
****
***
b
Un
tre
ate
d
1%
Me
Pr
e
Ike
rvi
s
ve
h lke
rvi
s
0
50
100
150
200
250
Im
pr
ov
em
en
t (
%
)
Lacrimation improvement at day 10
Fig. 1. (A) Tear volume over time as evaluated by the Phenol Red Thread test. *p < 0.05; **p < 0.01; ****p < 0.0001, non parametric Friedman test for repeated measures. (B)
Percentage of lacrimation improvement at day 10. Values are mean ± SD.
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ranging from 11.0 ± 2.0 to 12.0 ± 1.7 (mean ± SD, n ¼ 10) compared
to the average CFS scores ranging from 2.0 ± 1.0 to 3.0 ± 1.5
(mean ± SD, n ¼ 10) before dry eye induction (Fig. 2A). After 7 days
of treatment (day 10), all treated groups showed a signiﬁcant
reduction in their CFS scores (Fig. 2B) when compared to the un-
treated group. Ikervis and Ikervis vehicle treatments steadily
decreased mean CFS scores over time, with a reduction that was
statistically signiﬁcant (p < 0.05) after 3 and 7 days of treatment for
Ikervis. At the end of the treatment period, the Ikervis vehicle and
Ikervis reduced CFS, with a mean CFS score decreasing from
11.9 ± 2.0 (day 3) to 8.6 ± 2.8 (day 10) and from 12.0 ± 1.7 (day 3) to
5.4 ± 2.0 (day 10, p < 0.001). 1% methylprednisolone treatment also
decreased the average CFS scores (day 6) but the reduction did not
seem to progress between days 6 and 10. By contrast, untreatedanimals did not have their average CFS score reduced over time. By
the end of the treatment period the mean CFS score was degraded
to 13.3 ± 1.4 (p < 0.001;þ24.6 ± 21.2%) when compared to day 3. At
the end of the treatment period the mean reduction (in %) of the
CFS scores was statistically signiﬁcant for each treatment group
(p < 0.01) when compared to the untreated animals (Fig. 2B). The
average reduction in CFS was signiﬁcantly better for Ikervis
(54.9 ± 15.1%) when compared to its vehicle (24.3 ± 24.4%;
p < 0.01) or to 1% methylprednisolone (6.3 ± 38.0%, p < 0.0001).
4. Discussion
DED is a multifactorial disease of the ocular surface, with tear
ﬁlm instability (Yokoi et al., 1996, 2015) and inﬂammation being
essential in both the development and the exacerbation of the
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Fig. 2. (A) Corneal lesions change over time as measured by corneal ﬂuorescein score at baseline (before dry eye induction), at day 3 (before treatment) and at days 6 and 10.
*p < 0.05; **p < 0.01; ****p < 0.0001, non parametric Friedman test for repeated measures. (B) Percentage of CFS score reduction at day 10. Values are mean ± SD. **p < 0.01;
***p < 0.001; ****p < 0.0001, Cochran-Mantel-Haenszel test for comparison between groups.
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eye drops with dexamethasone, methylprednisolone, loteprednol
etabonate, and CsA become part of the armamentarium used for
the management of DED (Gumus and Cavanagh, 2009; Pﬂugfelder,
2004; Stonecipher et al., 2005). However, the side effects associated
with the use of glucocorticoids limit their usage to short-term
treatments, and to the most severe DED cases (Marsh and
Pﬂugfelder, 1999). Aqueous based tear substitutes are commonly
used to alleviate the symptoms of dry eye in DED patients. They
function by restoring the aqueous phase of the TF, and as such, have
proven to be effective in the management of mild to moderate
symptoms of DED (McCann et al., 2012; Uchiyama et al., 2008).Recently, lipid-containing eye drops, such as cationic emulsion eye
drops, were developed as a new tear ﬁlm oriented therapy (TFOT)
for the management of DED signs and symptoms (Lallemand et al.,
2012). They function by contributing in the restoration of a normal
precorneal TF by bringing oil to replenish a deﬁcient TFLL and
helping in its stabilization (Georgiev et al., 2016), this is especially
useful in the case of MGD patients, and a hypo- to iso-osmolar
aqueous phase to decrease TF osmolarity (Ismail et al., 2014;
Ousler et al., 2015; Robert et al., 2016). In addition, these cationic
emulsions, through their improved residence time on the ocular
surface are also very effective drug delivery vehicles for lipophilic
drugs (eg. CsA or latanoprost) (Daull et al., 2012, 2014, 2013).
P. Daull et al. / Experimental Eye Research 153 (2016) 159e164 163The aim of the present study was to evaluate the clinical efﬁcacy
of Ikervis, a cationic emulsion of CsA (Leonardi et al., 2015), and its
vehicle in an animal model of dry eye with severe alterations of the
corneal epithelium. For that purpose we used a validated mouse
model of dry eye, with 1% methylprednisolone as comparator
(Barabino et al., 2005; Okanobo et al., 2012). The data demonstrate
that in this model the cationic emulsion of CsA (Ikervis) tend to
restore tear secretion (Fig. 1) and was effective at decreasing
corneal epithelium damages, as evaluated by CFS scores (Fig. 2A).
However, the variability in the measurement of tear secretion with
the PRT test limits its usefulness as an efﬁcacy marker (Barabino
et al., 2014). Surprisingly, the cationic emulsion of CsA was signif-
icantly better (p < 0.0001) than 1% methylprednisolone treatment
(Fig. 2B). These data demonstrate that CsA eye drops are effective
for the management of DED signs, which was not unexpected
considering the long history of use of CsA eye drop formulations for
treating DED patients (Sall et al., 2000, 2006; Schultz, 2014; Zhou
and Wei, 2014).
Interestingly, the cationic vehicle itself was effective on CFS. It
signiﬁcantly reduced the corneal damages by approximately 25%
(Fig. 2B), and was not statistically different from the reference 1%
methylprednisolone. It is worth noting that the 1% methylpred-
nisolone did not perform as well as in the study by Okanobo and
collaborators who describe a CFS reduction close to 55% (Okanobo
et al., 2012). While classical artiﬁcial tears (ie., aqueous based so-
lution eye drops) are effective in the transient relief of DED
symptoms, their efﬁcacy on clinical signs is modest (Ismail et al.,
2014). Indeed, repeated instillations of tear substitutes in the
mouse model of dry eye were not very effective at reducing the
corneal epithelium damages as evidenced by a marginal but sta-
tistically signiﬁcant reduction of CFS scores (Quentric et al., 2016).
The present performance of the Ikervis vehicle (ie. an artiﬁcial tear-
like emulsion) on CFS was unexpected, and suggests that a TFOT
strategy aiming at restoring a healthy TF, with an optimized eye
drop formulation is a successful approach. In addition, those
cationic emulsions seem to harbor intrinsic anti-inﬂammatory
properties too (Daull et al., 2016; Liang et al., 2012) that may
contribute to their good performance in animal models and pa-
tients (Amrane et al., 2014; Ismail et al., 2014; Ousler et al., 2015).
It appears that the combination of a TFOT with anti-
inﬂammatory drugs; i.e., an optimized eye drop vehicle combined
with CsA, represents the optimal strategy for the concomitant
management of DED signs and symptoms. In that respect, the
cationic emulsion of CsA (Ikervis) (Leonardi et al., 2015, 2016), sets
up a new paradigm for the treatment of DED.
Taken together, we have shown a signiﬁcant improvement of
the clinical signs of DED in mice-treated with Ikervis, hence con-
ﬁrming the role of anti-inﬂammatory therapy for the treatment of
DED. The efﬁcacy of the cationic emulsion vehicle itself demon-
strates that a TFOT with an optimized lipid containing artiﬁcial tear
vehicle can also be effective on DED signs.
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